718 results on '"Ghany, Marc G."'
Search Results
2. Human immunodeficiency virus coinfection differentially impacts hepatitis B virus viral markers based on hepatitis Be antigen status in patients with suppressed viremia
Catalog
Books, media, physical & digital resources
3. Characteristics of Older Patients With Immunotolerant Chronic Hepatitis B Virus Infection
4. Low Rate of Hepatitis B Reactivation Among Patients with Chronic Hepatitis C During Direct Acting Antiviral Therapy
5. Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference
6. Randomized Trial of a Vaccine Regimen to Prevent Chronic HCV Infection
7. Hepatitis B RNA and Core-Related Antigen Provide Value Beyond DNA in Evaluating e But Not Surface Antigen Clearance
8. A Prospective Cohort Study of Novel Markers of Hepatitis B Virus Replication in Human Immunodeficiency Virus Coinfection
9. Current Best Practice in Hepatitis B Management and Understanding Long-term Prospects for Cure
10. Age, race and viral genotype are associated with the prevalence of hepatitis B e antigen in children and adults with chronic hepatitis B
11. Trends in hepatocellular carcinoma and viral hepatitis treatment in older Americans.
12. Performance of Serum-Based Scores for Identification of Mild Hepatic Steatosis in HBV Mono-infected and HBV–HIV Co-infected Adults
13. Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
14. Serum neutralization activity declines but memory B cells persist after cure of chronic hepatitis C
15. REPLY: The exact predictive value of HBcrAg and HBV RNA in serological status and disease activity in CHB
16. Prospective phenotyping of NGLY1-CDDG, the first congenital disorder of deglycosylation
17. Hepatitis B: Current Status of Therapy and Future Therapies
18. Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad
19. Durability of Spontaneous and Treatment-Related Loss of Hepatitis B s Antigen
20. Enhanced Screening for Hepatitis D in the USA: Overcoming the Delta Blues
21. Diabetes and prediabetes in patients with hepatitis B residing in North America
22. Characteristics of Adults in the Hepatitis B Research Network in North America Reflect Their Country of Origin and Hepatitis B Virus Genotype
23. Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection
24. WHO Guidelines for Prevention, Care and Treatment of Individuals Infected with HBV: A US Perspective
25. Longitudinal effects of Nucleos(t)ide analogue therapy in chronic hepatitis B patients and the utility of non-invasive fibrosis markers during treatment: A single-center experience for up to 17 years
26. Tools Needed to Support Same-Day Diagnosis and Treatment of Current Hepatitis C Virus Infection.
27. Hepatitis B Vaccine: Four Decades on.
28. Joint statement in support of hepatitis C human challenge studies
29. Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C
30. Controlled Human Infection Model for Hepatitis C Virus Vaccine Development: Trial Design Considerations
31. A Glimmer of Hope for an Orphan Disease
32. Natural History of Chronic Hepatitis C
33. Hepatitis B cure: From discovery to regulatory approval
34. Current treatment guidelines of chronic hepatitis B: The role of nucleos(t)ide analogues and peginterferon
35. Hepatitis A, B, D, And E
36. Use of HBV RNA and to predict change in serological status and disease activity in CHB
37. Hepatitis B Virus–Specific and Global T-Cell Dysfunction in Chronic Hepatitis B
38. Joint statement in support of hepatitis C human challenge studies
39. Association of Alanine Aminotransferase Flares to Hepatitis B Surface Decline During Tenofovir Alone or With Pegylated Interferon Alfa.
40. Patients With Compensated Hepatitis B Virus-Related Cirrhosis and Low-Level Viremia: Treat or Not to Treat?
41. Immunostaining for Hepatitis B Viral Antigens in Liver: Association with Clinical, Biochemical and Virologic Features of Disease
42. Moving the Needle to Reduce Acetaminophen (Paracetamol) Hepatotoxicity
43. Natural History of Hepatitis C
44. Characteristics of Adults in the Hepatitis B Research Network in North America Reflect Their Country of Origin and Hepatitis B Virus Genotype
45. Durability of Antibody Response Against Hepatitis B Virus in Healthcare Workers Vaccinated as Adults
46. Randomized Trial of Tenofovir With or Without Peginterferon Alfa Followed by Protocolized Treatment Withdrawal in Adults With Chronic Hepatitis B
47. Hepatitis A, B, D, and E
48. Hepatitis B and D
49. Withdrawal of Long-Term Nucleotide Analog Therapy in Chronic Hepatitis B: Outcomes From the Withdrawal Phase of the HBRN Immune Active Treatment Trial.
50. Randomized Trial of Tenofovir With or Without Peginterferon Alfa Followed by Protocolized Treatment Withdrawal in Adults With Chronic Hepatitis B.
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.